title: Covalent modification of cell surfaces with TLR agonists improves & directs immune stimulation.
abstract: We present a primary example of a cell surface modified with a synergistic combination of agonists to tune immune stimulation. A model cell line, Lewis Lung Carcinoma, was covalently modified with CpG-oligonucleotides and lipoteichoic acid, both Toll-like receptor (TLR) agonists. The immune-stimulating constructs provided greater stimulation of NF-κB in a model cell line and bone marrow-derived dendritic cells than the components unconjugated in solution.
authors.affiliation: Department of Chemistry, University of California Irvine, Irvine, CA 92697, USA. aesserka@uci.edu.
authors.forename: Janine K
authors.initials: JK
authors.lastname: Tom
authors.forename: Rock J
authors.initials: RJ
authors.lastname: Mancini
authors.forename: Aaron P
authors.initials: AP
authors.lastname: Esser-Kahn
mesh_terms: D000818:Animals; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy* / Q000276:immunology; D045744:Cell Line, Tumor; D008070:Lipopolysaccharides / Q000737:chemistry / Q000494:pharmacology*; D016328:NF-kappa B / Q000276:immunology; D009838:Oligodeoxyribonucleotides / Q000737:chemistry / Q000494:pharmacology*; D013682:Teichoic Acids / Q000737:chemistry / Q000494:pharmacology*; D051193:Toll-Like Receptors / Q000819:agonists* / Q000276:immunology
chemical_list: C408982:CPG-oligonucleotide; D008070:Lipopolysaccharides; D016328:NF-kappa B; D009838:Oligodeoxyribonucleotides; D013682:Teichoic Acids; D051193:Toll-Like Receptors; C009900:lipoteichoic acid
references.citation: J Am Chem Soc. 2009 Dec 2;131(47):17090-2
references.pmid: 19888723
references.citation: PLoS One. 2012;7(8):e43612
references.pmid: 22952720
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4378-83
references.pmid: 19255430
references.citation: Immunol Rev. 2004 Jun;199:227-50
references.pmid: 15233738
references.citation: Science. 2012 Jul 27;337(6093):431-5
references.pmid: 22837519
references.citation: J Med Chem. 2012 Feb 9;55(3):1106-16
references.pmid: 22239408
references.citation: Nat Rev Immunol. 2009 Oct;9(10):741-7
references.pmid: 19763148
references.citation: Adv Drug Deliv Rev. 2009 Mar 28;61(3):195-204
references.pmid: 19211030
references.citation: J Biol Chem. 1999 Jun 18;274(25):17406-9
references.pmid: 10364168
references.citation: Immunity. 2010 Oct 29;33(4):492-503
references.pmid: 21029960
references.citation: J Exp Med. 1999 Dec 20;190(12):1909-14
references.pmid: 10601366
references.citation: Cell. 2012 Mar 16;148(6):1284-92
references.pmid: 22424235
references.citation: Clin Vaccine Immunol. 2007 Dec;14(12):1629-33
references.pmid: 17928431
references.citation: J Vis Exp. 2008 Jul 09;(17):
references.pmid: 19066518
references.citation: Annu Rev Immunol. 2002;20:709-60
references.pmid: 11861616
references.citation: Adv Mater. 2012 Jul 24;24(28):3724-46
references.pmid: 22641380
references.citation: Angew Chem Int Ed Engl. 2012 Apr 16;51(16):3862-6
references.pmid: 22411781
references.citation: Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):1080-5
references.pmid: 22247289
references.citation: Annu Rev Immunol. 2002;20:197-216
references.pmid: 11861602
references.citation: Curr Opin Immunol. 2000 Feb;12(1):35-43
references.pmid: 10679406
references.citation: Angew Chem Int Ed Engl. 2011 Jul 25;50(31):7052-5
references.pmid: 21688362
references.citation: PLoS One. 2012;7(1):e30596
references.pmid: 22299046
references.citation: J Leukoc Biol. 2010 Jul;88(1):189-99
references.pmid: 20360404
references.citation: Integr Biol (Camb). 2013 Apr;5(4):650-8
references.pmid: 23443913
references.citation: Immunol Today. 2000 Oct;21(10):521-6
references.pmid: 11071532
references.citation: Nature. 2011 Feb 24;470(7335):543-7
references.pmid: 21350488
references.citation: Blood. 2011 Jan 6;117(1):118-27
references.pmid: 20876455
references.citation: Jpn J Cancer Res. 1992 Nov;83(11):1128-31
references.pmid: 1483927
references.citation: Nat Mater. 2009 Feb;8(2):151-8
references.pmid: 19136947
references.citation: Infect Immun. 1996 Jun;64(6):1906-12
references.pmid: 8675286
references.citation: Expert Opin Ther Pat. 2011 Jun;21(6):927-44
references.pmid: 21406035
references.citation: Cancer Immunol Immunother. 2011 May;60(5):659-69
references.pmid: 21318638
references.citation: J Leukoc Biol. 2009 Apr;85(4):664-72
references.pmid: 19164128
references.citation: J Immunol. 2011 May 15;186(10):5916-26
references.pmid: 21482737
references.citation: Clin Vaccine Immunol. 2013 Mar;20(3):427-32
references.pmid: 23345580
references.citation: Langmuir. 2009 Jun 16;25(12):6985-91
references.pmid: 19505164
references.citation: Adv Funct Mater. 2013 Jan 14;23(2):161-172
references.pmid: 23503923
references.citation: Annu Rev Immunol. 2000;18:767-811
references.pmid: 10837075
references.citation: Sci Transl Med. 2012 Aug 22;4(148):148rv9
references.pmid: 22914624
references.citation: Nature. 2007 Sep 27;449(7161):419-26
references.pmid: 17898760
references.citation: Immunol Rev. 2011 Jan;239(1):178-96
references.pmid: 21198672
references.citation: Microbiol Immunol. 1992;36(9):983-97
references.pmid: 1281260